175 related articles for article (PubMed ID: 36669148)
41. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
42. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
[TBL] [Abstract][Full Text] [Related]
43. Utility of Global Longitudinal Strain by Echocardiography to Detect Left Ventricular Dysfunction in Long-Term Adult Survivors of Childhood Lymphoma and Acute Lymphoblastic Leukemia.
Christiansen JR; Massey R; Dalen H; Kanellopoulos A; Hamre H; Fosså SD; Ruud E; Kiserud CE; Aakhus S
Am J Cardiol; 2016 Aug; 118(3):446-52. PubMed ID: 27296561
[TBL] [Abstract][Full Text] [Related]
44. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
Jones RL; Wagner AJ; Kawai A; Tamura K; Shahir A; Van Tine BA; Martín-Broto J; Peterson PM; Wright J; Tap WD
Clin Cancer Res; 2021 Jul; 27(14):3861-3866. PubMed ID: 33632930
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
46. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
47. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
[TBL] [Abstract][Full Text] [Related]
48. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
49. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM; Geurts YM; Aleman BMP; Lugtenburg PJ; Rademakers SE; de Weijer RJ; Schippers MGA; Ta BDP; Plattel WJ; Zijlstra JM; van der Maazen RWM; Nijziel MR; Ong F; Schimmel EC; Posthuma EFM; Kersten MJ; Böhmer LH; Muller K; Koene HR; Te Boome LCJ; Bilgin YM; de Jongh E; Janus CPM; van Leeuwen FE; Schaapveld M
J Clin Oncol; 2024 Jun; 42(16):1903-1913. PubMed ID: 38359378
[TBL] [Abstract][Full Text] [Related]
50. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.
Tahover E; Segal A; Isacson R; Rosengarten O; Grenader T; Gips M; Cherny N; Heching NI; Mesika L; Catane R; Gabizon A
Anticancer Drugs; 2017 Aug; 28(7):787-794. PubMed ID: 28562379
[TBL] [Abstract][Full Text] [Related]
51. Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group.
Lipshultz ER; Chow EJ; Doody DR; Armenian SH; Asselin BL; Baker KS; Bhatia S; Constine LS; Freyer DR; Kopp LM; Schwartz CL; Lipshultz SE; Vrooman LM
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):536-542. PubMed ID: 34810210
[TBL] [Abstract][Full Text] [Related]
52. Impaired exercise capacity and left ventricular function in long-term adult survivors of childhood acute lymphoblastic leukemia.
Christiansen JR; Kanellopoulos A; Lund MB; Massey R; Dalen H; Kiserud CE; Ruud E; Aakhus S
Pediatr Blood Cancer; 2015 Aug; 62(8):1437-43. PubMed ID: 25832752
[TBL] [Abstract][Full Text] [Related]
53. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Getz KD; Sung L; Alonzo TA; Leger KJ; Gerbing RB; Pollard JA; Cooper T; Kolb EA; Gamis AS; Ky B; Aplenc R
J Clin Oncol; 2020 Jul; 38(21):2398-2406. PubMed ID: 32343641
[TBL] [Abstract][Full Text] [Related]
54. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
55. Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines.
Pourier MS; Mavinkurve-Groothuis AMC; Dull MM; Weijers G; Loonen J; Bellersen L; de Korte CL; Kapusta L
Am J Cardiol; 2020 Jul; 127():163-168. PubMed ID: 32444028
[TBL] [Abstract][Full Text] [Related]
56. Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia.
Goldberg JM; Scully RE; Sallan SE; Lipshultz SE
J Pediatr Hematol Oncol; 2012 Jul; 34(5):395-7. PubMed ID: 22584777
[TBL] [Abstract][Full Text] [Related]
57. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
[TBL] [Abstract][Full Text] [Related]
58. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
60. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]